VERSANT Hepatitis B Virus DNA 3.0 검사와 Digene Hybrid Capture II Hepatitis B Virus DNA 검사의 비교 및 B형 간염 임상상과의 관련성 = Comparison of VERSANT Hepatitis B Virus DNA 3.0 Assay with Digene Hybrid Capture II Hepatitis B Virus DNA Test in Relation to Clinical Status of Hepatitis B Virus

국문 초록 (Abstract)

배경 : B형 간염 바이러스(hepatitis B virus, HBV) DNA정량검사는 임상검사실에서 널리 이용되고 있으나, 서로 다른 검사방법 간에 표준화가 되어 있지 않으며, 한국인 B형 간염 환자에서 임상적 유용성에 대해 명확히 규명되지 않았다.방법 : 232명의 한국인 B형 간염 환자를 대상으로 Bayer VE-RSANT HBV DNA 3.0 Assay (VERSANT 3.0)를 DigeneHybrid Capture II HBV DNA 검사(HC-II)와 비교하고 HBeAg과 혈청 ALT 농도에 따라 평가하였다. HC-II로 검출한계 이하인 117예를 Real-Q 정량 PCR (BioSewoom, Korea)로 추가 분석하였다.결과 : VERSANT 3.0과 HC-II는 우수한 상관계를 보였으나(r=0.9739), VERSANT 3.0의 결과(copies/mL)는 HC-II의결과(copies/mL)에 비해 0.45 log10 높았다. HBV DNA 농도는HBeAg 양성군에서 HBeAg 음성군에 비해 유의하게 높았으며(P=0.002), 비정상 ALT군에서 정상 ALT군에 비해 유의하게높았다(P<0.0001). VERSANT 3.0의 HBV DNA 검출률은HBeAg 음성이고 정상 ALT군(n=68)에서 HBeAg 양성이고비정상 ALT군(n=164)에 비해 유의하게 낮았다(35.3% vs 89.6%, P<0.0001). VERSANT 3.0으로 HBV가 검출되지 않은 61예중 52예는 Real-Q에서 검출 가능하였으며 평균 3.26 log10 copies/mL의 값을 보였다.

참고문헌 (Reference)

1 "만성 B형 간질환 환자의라미부딘내성 예측인자" 13 : 157-165, 2007

2 "User verification of per-formance for precision and trueness; approved guideline-secondedition, CLSI document EP15-A2" Wayne, PA: Clinical and Labora-tory Standards Institute 2005

3 "The value of quantitative detection of HBV-DNA amplified byPCR in the study of hepatitis B infection" 24 : 680-685, 1996

4 "Routine detection and quantification of hepatitis B virus DNAin clinical laboratories: performance of three commercial assays" 85 : 11-21, 2000

5 "Real-time PCR assay for detection and quantification of hepatitis B virus genotypes A to G" 44 : 3325-3333, 2006

6 "Predictorsof lamivudine resistance in patients with chronic hepatitis B virusinfection" 13 : 157-165, 2007

7 "Overview of commercial HBV assays systems" 95 : 3-13, 2004

8 "Multicenter evaluation of the VERSANT hepatitis B virus DNA 3.0assay" 42 : 800-806, 2004

9 "Monitoring the virus load can predict theemergence of drug-resistant hepatitis B virus strains in renal trans-plantation patients during lamivudine therapy" 181 : 2063-2066, 2000

10 "Guideline for the treatment of chronic hepatitis B virus infection" 10 : S89-S100, 2004

11 "Evaluation of the COBASAmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis Bvirus (HBV) quantitative test and comparison to the VERSANTHBV DNA 3.0 assay" 44 : 1390-1399, 2006

12 "Evaluation of precisionperformance of quantitative measurement methods; approved gui-deline-second edition, CLSI document EP5-A2EP5-A2. 2004." Wayne, PA:Clinical and Laboratory Standards Institute 2004

13 "Comparison ofthree different sensitive assays for hepatitis B virus DNA in moni-toring of responses to antiviral therapy" 38 : 3205-3208, 2000

14 "Comparison of the second-generation digene hybrid capture assay with the branched-DNAassay for measurement of hepatitis B virus DNA in serum" 37 : 2461-2465, 1999

15 "Comparing methods of measurement:why plotting difference against standard method is misleading" 346 : 1085-1087, 1995

16 "Com-parison of commercial assays for the quantification of HBV DNAload in health care workers: calibration differences" 100 : 37-47, 2002

17 "Clini-cal evaluation of the COBAS Amplicor HBV monitor test for mea-suring serum HBV DNA and comparison with the Quantiplexbranched DNA signal amplification assay in Taiwan" 57 : 141-145, 2004

18 "Aone-year trial of lamivudine for chronic hepatitis B. Asia HepatitisLamivudine Study Group" 339 : 61-68, 1998

19 "An overview of assays for serum HBV DNA" 46 : 609-614, 2000

20 "2004년대한간학회 B형만성간염치료가이드라인" 10 : S89-S100, 2004